MedTrace Logo

Comparing 2 Types of Pain Relief After Cesarean Delivery: Spinal Morphine and TAP Block

NCT00799955 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2013-01-23

No results posted yet for this study

Summary

Summary Brief Summary Standard care for pain relief after cesarean delivery is spinal morphine. Spinal morphine may be unsuitable for patients having general anesthetic or prior morphine-related side effects and can be less effective in patients with morphine tolerance. An alternative is a TAP block where local anesthetic is deposited between the abdominal muscles consequently numbing the area and providing pain relief. The investigators believe a TAP block will provide equivalent pain relief to spinal morphine.

Conditions

  • Cesarean Delivery

Interventions

PROCEDURE

Placebo block

100 micrograms of spinal morphine

PROCEDURE

Ultrasound-guided TAP block

1.5mg/kg of 0. 5% ropivacaine (to maximum dose of 20 mls = 100mg on each side) will be injected into the transversus abdominis plane, on each side

Sponsors & Collaborators

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Roanne Preston, MD, FRCPC · University of British Columbia

  • Heather Loane, MBBS, B.Med.Sci · University of British Columbia

  • Joanne Douglas, MD, FRCPC · University of British Columbia

  • Simon Massey, MB BCh, MRCP, FRCA · University of British Columbia

  • Jessica Tyler, BSc · University of British Columbia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2010-04-30
Completion
2010-04-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00799955 on ClinicalTrials.gov